These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 23335239)

  • 1. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
    Cooper TM; Razzouk BI; Gerbing R; Alonzo TA; Adlard K; Raetz E; Gamis AS; Perentesis J; Whitlock JA
    Pediatr Blood Cancer; 2013 Jul; 60(7):1141-7. PubMed ID: 23335239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
    Cooper TM; Alonzo TA; Gerbing RB; Perentesis JP; Whitlock JA; Taub JW; Horton TM; Gamis AS; Meshinchi S; Loken MR; Razzouk BI
    Cancer; 2014 Aug; 120(16):2482-9. PubMed ID: 24771494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
    Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P
    Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
    Hijiya N; Thomson B; Isakoff MS; Silverman LB; Steinherz PG; Borowitz MJ; Kadota R; Cooper T; Shen V; Dahl G; Thottassery JV; Jeha S; Maloney K; Paul JA; Barry E; Carroll WL; Gaynon PS
    Blood; 2011 Dec; 118(23):6043-9. PubMed ID: 21967976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
    Advani AS; Gundacker HM; Sala-Torra O; Radich JP; Lai R; Slovak ML; Lancet JE; Coutre SE; Stuart RK; Mims MP; Stiff PJ; Appelbaum FR
    Br J Haematol; 2010 Dec; 151(5):430-4. PubMed ID: 21113977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
    Steinherz PG; Shukla N; Kobos R; Steinherz L
    Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.
    Shukla N; Kobos R; Renaud T; Steinherz LJ; Steinherz PG
    Pediatr Blood Cancer; 2014 Mar; 61(3):431-5. PubMed ID: 24115731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
    Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
    Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
    Hijiya N; Gaynon P; Barry E; Silverman L; Thomson B; Chu R; Cooper T; Kadota R; Rytting M; Steinherz P; Shen V; Jeha S; Abichandani R; Carroll WL
    Leukemia; 2009 Dec; 23(12):2259-64. PubMed ID: 19741725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
    Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
    J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clofarabine combinations as acute myeloid leukemia salvage therapy.
    Faderl S; Ferrajoli A; Wierda W; Huang X; Verstovsek S; Ravandi F; Estrov Z; Borthakur G; Kwari M; Kantarjian HM
    Cancer; 2008 Oct; 113(8):2090-6. PubMed ID: 18756533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
    Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
    Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report.
    Gidwani P; Ramesh KH; Liu Y; Kolb EA
    Chemotherapy; 2008; 54(2):120-4. PubMed ID: 18303261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.
    Abd Elmoneim A; Gore L; Ricklis RM; Boklan J; Cooper T; Narendran A; Rolla K; Scott T; Arceci RJ
    Pediatr Blood Cancer; 2012 Dec; 59(7):1252-8. PubMed ID: 22887831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
    Agura E; Cooper B; Holmes H; Vance E; Berryman RB; Maisel C; Li S; Saracino G; Tadic-Ovcina M; Fay J
    Oncologist; 2011; 16(2):197-206. PubMed ID: 21273514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
    Scappini B; Gianfaldoni G; Caracciolo F; Mannelli F; Biagiotti C; Romani C; Pogliani EM; Simonetti F; Borin L; Fanci R; Cutini I; Longo G; Susini MC; Angelucci E; Bosi A
    Am J Hematol; 2012 Dec; 87(12):1047-51. PubMed ID: 23151979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
    van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
    Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
    Koh K; Ogawa C; Okamoto Y; Kudo K; Inagaki J; Morimoto T; Mizukami H; Ecstein-Fraisse E; Kikuta A
    Int J Hematol; 2016 Aug; 104(2):245-55. PubMed ID: 27086352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clofarabine in pediatric acute leukemia: current findings and issues.
    Hijiya N; Barry E; Arceci RJ
    Pediatr Blood Cancer; 2012 Sep; 59(3):417-22. PubMed ID: 22354543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia.
    O'Connor D; Sibson K; Caswell M; Connor P; Cummins M; Mitchell C; Motwani J; Taj M; Vora A; Wynn R; Kearns PR
    Br J Haematol; 2011 Aug; 154(4):482-5. PubMed ID: 21689087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.